EUGENE ABRAMSON, M.D.; DANA WILSON, M.D.; RONALD A. ARKY, M.D.
Phycomycosis is the most acutely fatal fungal disease known (1). Not described in this country until 1943 (2), its prevalence appears to be increasing, concurrently with and perhaps related to the rising rate of antibiotic use. Before the mid-1950's the prognosis was considered "hopeless" (3). Since the introduction of amphotericin B, considerable evidence of its effectiveness in such fungal infections as blastomycosis and cryptococcosis has accrued. Published reports of its use in phycomycosis are few, however. We have recently followed two cases of rhinocerebral phycomycosis arising in association with diabetic ketoacidosis and treated with amphotericin B. This paper presents further
ABRAMSON E, WILSON D, ARKY RA. Rhinocerebral Phycomycosis in Association with Diabetic Ketoacidosis: Report of Two Cases and a Review of Clinical and Experimental Experience with Amphotericin B Therapy. Ann Intern Med. ;66:735–742. doi: 10.7326/0003-4819-66-4-735
Download citation file:
Published: Ann Intern Med. 1967;66(4):735-742.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use